Nodakenin Exhibits Anxiolytic-like and Anti-depressant-like Effects in the Experimental Mice Models

ABSTRACT

Background: Anxiety and depression are among the most widespread mental health conditions worldwide, impacting millions and imposing a considerable burden on individuals and healthcare systems. Objectives: The present research work was dedicated to examining the therapeutic values of nodakenin against anxiolytic and depressive-like conditions in an experimental mice model. Materials and Methods: The experimental Swiss mice were administered 25 and 50 mg/kg of nodakenin and/or 20 mg/kg of imipramine, a standard anti-depressive drug. Various behavioral examinations, such as forced swimming, tail suspension, open field test, elevated plus-maze, and light and dark exploration tests, were performed to investigate the anxiolytic and anti-depressant properties of the nodakenin. Furthermore, the activity of monoamine oxidase-A (MAO-A) was assessed in the brain tissues of the experimental mice using a test kit. Results: The present results indicated that nodakenin treatment reduced the immobility period, elevated the swimming duration in the forced swimming test, and reduced the immobility period in the tail immersion test. The nodakenin treatment considerably increased the exploratory behavior of the experimental mice. The results of the elevated plus maze test and light–dark box tests indicated the anti-depressant and anxiolytic properties of nodakenin in experimental mice. Furthermore, the nodakenin treatment also inhibited the MAO-A enzyme activity in the brain tissues of the experimental mice. Conclusion: The current research demonstrates that the nodakenin treatment exhibits anxiolytic and anti-depressant properties in murine models. The present findings indicate the therapeutic potential of nodakenin as an alternate treatment for comorbid anxiety and depression conditions.

KEYWORDS

• Anxiety
• depression
• elevated plus-maze test
• imipramine
• nodakenin

Showing references and in-text citations exactly as published.

• DOI10.1177/09731296251348082Copy

RELATED ARTICLES

Matched on section and article type within this issue of Pharmacogn. Mag..

• Article · VOLUME 21, ISSUE 4Reserpine Ameliorates 1,2-Dimethylhydrazineinduced Colon Cancer through Regulating Xenobiotic Enzymes and Bax/Caspases/Bcl2-mediated Apoptotic Mechanisms in RatsWenli He, Lina He · pp. 1165–1175Original Research ArticleSame type: Article
• Article · VOLUME 21, ISSUE 4Study on the Neuroprotective Mechanism of Salidroside Modified with Polydopamine Nanoparticles in Regulating Notch Pathway by Inhibiting miR-155 in Stroke Ratsactivity of AQP, TLR TLR, Song Liu, Xiaomeng Lv, Dong Wang · pp. 1176–1186Original Research ArticleSame type: Article
• Article · VOLUME 21, ISSUE 4Exploring Beta-sitosterol’s Role in Breast Cancer Treatment via Integrated Network Pharmacological Analysis and in vitro ValidationJiaxing Yu, Shuqin Cheng, Zelin Ye, Ming Zhang, Xinlei Zhao · pp. 1201–1211Original Research ArticleSame type: Article
• Article · VOLUME 21, ISSUE 4Artemetin Inhibits Cell Growth and Activates Caspase-dependent Apoptotic Cell Death Colon Cancer HCT-116 CellsYan Chen, Lu Men · pp. 1212–1219Original Research ArticleSame type: Article